Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.21.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 43,326 $ 28,193
Marketable securities 82,132 118,130
Accrued interest receivable 265 277
Prepaid research and development expenses 5,631 2,221
Other prepaid expenses and current assets 1,919 2,764
Total current assets 133,273 151,585
Property and equipment, net 1,690 1,761
Operating lease right-of-use asset 273 272
Other assets 1,446 207
Total assets 136,682 153,825
Current liabilities:    
Accounts payable 1,606 231
Accrued research and development expenses 3,294 4,698
Other accrued liabilities 3,009 4,928
Total current liabilities 7,909 9,857
Long-term portion of operating lease liability 1,127 1,262
Total liabilities 9,036 11,119
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $0.0001 par value: 200,000,000 shares authorized; 68,946,092 and 68,946,092 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively 7 7
Additional paid-in capital 822,054 819,549
Accumulated other comprehensive income (6) 8
Accumulated deficit (694,409) (676,858)
Total stockholders' equity 127,646 142,706
Total liabilities and stockholders' equity $ 136,682 $ 153,825